These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29932084)

  • 41. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
    Muñoz de Benito RM; Arribas López JR
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.
    Arribas JR; DeJesus E; van Lunzen J; Zurawski C; Doroana M; Towner W; Lazzarin A; Nelson M; McColl D; Andreatta K; Swamy R; Szwarcberg J; Nguyen T
    HIV Clin Trials; 2017 May; 18(3):118-125. PubMed ID: 28555519
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
    Maitland D; Moyle G; Hand J; Mandalia S; Boffito M; Nelson M; Gazzard B
    AIDS; 2005 Jul; 19(11):1183-8. PubMed ID: 15990571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    ; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
    AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
    Blanco JR; Caro-Murillo AM; Castaño MA; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Riera M; Pulido F; Vera F; Romero-Palacios A; Aguirrebengoa K; Portilla J; Ferrer P; Pedrol E
    HIV Clin Trials; 2013; 14(5):204-15. PubMed ID: 24144897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
    Kabbara WK; Ramadan WH
    J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.
    Gay CL; Willis SJ; Cope AB; Kuruc JD; McGee KS; Sebastian J; Crooks AM; McKellar MS; Margolis DM; Fiscus SA; Hicks CB; Ferrari G; Eron JJ;
    AIDS; 2016 Nov; 30(18):2815-2822. PubMed ID: 27662549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study.
    Farmer A; Wang X; Ganesan A; Deiss RG; Agan BK; O'Bryan TA; Akers K; Okulicz JF
    AIDS Res Ther; 2016; 13():16. PubMed ID: 27006682
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen.
    Mathias AA; Hinkle J; Menning M; Hui J; Kaul S; Kearney BP;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):167-73. PubMed ID: 17667331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
    Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
    J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy.
    Shikuma CM; Kohorn L; Paul R; Chow DC; Kallianpur KJ; Walker M; Souza S; Gangcuangco LMA; Nakamoto BK; Pien FD; Duerler T; Castro L; Nagamine L; Soll B
    HIV Clin Trials; 2018 Aug; 19(4):139-147. PubMed ID: 30451595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
    Lortholary O; Roussillon C; Boucherie C; Padoin C; Chaix ML; Breton G; Rami A; Veziris N; Patey O; Caumes E; May T; Molina JM; Robert J; Tod M; Fagard C; Chêne G;
    J Antimicrob Chemother; 2016 Mar; 71(3):783-93. PubMed ID: 26679250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV.
    Munderi P; Were E; Avihingsanon A; Mbida PAM; Mohapi L; Moussa SB; Jansen M; Bicer C; Mohammed P; van Delft Y
    South Afr J HIV Med; 2019; 20(1):949. PubMed ID: 31392036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.
    Xu L; Peng W; Song X; Li Y; Han Y; Zhu T; Fu Q; Du X; Cao W; Li T
    BMC Infect Dis; 2021 Jan; 21(1):112. PubMed ID: 33485301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.
    Ocampo A; Domingo P; Fernández P; Diz J; Barberá JR; Sepúlveda MA; Salgado X; Rodriguez M; Santos J; Yzusqui M; Mayorga MI; Lorenzo JF; Bahamonde A; Bachiller P; Martínez E; Rozas N; Torres C; Muñoz A; Casado A; Podzamczer D
    J Antimicrob Chemother; 2018 Aug; 73(8):2171-2176. PubMed ID: 29788066
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study.
    Huang SH; Lin SW; Chang SY; Lin YT; Sun HY; Liu WC; Su YC; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2020 Feb; 53(1):60-68. PubMed ID: 29884449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy.
    Ajibola G; Rowley C; Maruapula D; Leidner J; Bennett K; Powis K; Shapiro RL; Lockman S
    South Afr J HIV Med; 2020; 21(1):1023. PubMed ID: 32158555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
    Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
    PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.